Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Relmada Therapeutics Inc
RLMD | US
4.45
USD0.02
0.45%
RLMD | US
About Relmada Therapeutics Inc
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
06/03/2026
Close
4.45
Open
4.40
High
4.70
Low
4.37
Relmada Therapeutics Inc. a clinical-stage biotechnology company focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone dextromethadone and REL-1017) a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables Florida.
View LessRLMD | US
Risk
84.4
Sharpe
10.68
Luna's Score
52/100
Recommendation
Hold
Luna says (RLMD | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
74.3%1 month
84.4%3 months
77.8%6 months
103.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.71
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
0.54
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-161.25M
MarketCap
134.28M
MarketCap(USD)
134.28M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-100.41
Short ratio
3.86
Short perc.
4.22
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.94
Range1M
1.69
Range3M
1.77
Volumes: Market Activity
Rel. volume
0.74
Price X volume
2.00M
